Head-to-head evidence
CS1001 Monoclonal Antibody vs KL-A167
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Non-Small Cell Lung Cancer
Shared mechanism: PD-L1 · full Non-Small Cell Lung Cancer pipeline
CS1001 Monoclonal Antibody
Developed by CStone Pharmaceuticals
NCT03728556 · Phase 3 · completed
In this randomized, quadruple-blind, placebo-controlled Phase 3 trial, 381 patients with stage III lung cancer who had completed chemoradiotherapy were randomized to sugemalimab or placebo. Sugemalimab significantly reduced the risk of progression or death compared with placebo (median progression-free survival 10.5 vs 6.2 months).
Caveat: this result is taken from a company announcement or a news report of one, not from the trial registry or a peer-reviewed publication. Treat the figures as the sponsor's own statement, not as independently verified evidence.
KL-A167
Developed by Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.
Next expected readout: December 2026 · NCT07108816 (registry estimate)
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: CS1001 Monoclonal Antibody's landscape · KL-A167's landscape